During the last session, Janux Therapeutics Inc (NASDAQ:JANX)’s traded shares were 0.79 million, with the beta value of the company hitting 2.86. At the end of the trading day, the stock’s price was $25.15, reflecting an intraday loss of -1.80% or -$0.46. The 52-week high for the JANX share is $71.71, that puts it down -185.13 from that peak though still a striking 10.62% gain since the share price plummeted to a 52-week low of $22.48. The company’s market capitalization is $1.49B, and the average intraday trading volume over the past 10 days was 0.87 million shares, and the average trade volume was 903.95K shares over the past three months.
Janux Therapeutics Inc (JANX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.21. JANX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Janux Therapeutics Inc (NASDAQ:JANX) trade information
Janux Therapeutics Inc (JANX) registered a -1.80% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.80% in intraday trading to $25.15, hitting a weekly high. The stock’s 5-day price performance is 2.86%, and it has moved by -4.15% in 30 days. Based on these gigs, the overall price performance for the year is -53.03%. The short interest in Janux Therapeutics Inc (NASDAQ:JANX) is 10.61 million shares and it means that shorts have 11.13 day(s) to cover.
The consensus price target of analysts on Wall Street is $58.5, which implies an increase of 57.01% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $41 and $76 respectively. As a result, JANX is trading at a discount of -202.19% off the target high and -63.02% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -67.90%. While earnings are projected to return -52.21% in 2025.
JANX Dividends
Janux Therapeutics Inc is due to release its next quarterly earnings on 2025-May-08. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Janux Therapeutics Inc (NASDAQ:JANX)’s Major holders
Janux Therapeutics Inc insiders own 6.69% of total outstanding shares while institutional holders control 117.03%, with the float percentage being 125.42%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 262.0 institutions own stock in it. As of 2024-06-30, the company held over 9.17 million shares (or 16.8326% of all shares), a total value of $383.95 million in shares.
The next largest institutional holding, with 7.78 million shares, is of FMR LLC’s that is approximately 14.2835% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $325.8 million.
Also, the Mutual Funds coming in first place with the largest holdings of Janux Therapeutics Inc (JANX) shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on May 31, 2025 indicates that Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund owns about 1.57 shares. This amounts to just over 2.65 percent of the company’s overall shares, with a $39.5 million market value. The same data shows that the other fund manager holds slightly less at 1.34, or about 2.27% of the stock, which is worth about $33.77 million.
